SE
SEOVF.US Sernova Corp
- Market cap
- USD 27.9M
- P/E
- 7.4x
- P/B
- 24.48x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jul 2026.
Is SEOVF.US undervalued?
Graham numberSEOVF.US trades 183.5% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sernova Corp fundamental analysis
No fundamental analysis for Sernova Corp yet.
Sernova Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sernova Corp
Sernova Biotherapeutics Inc operates as a clinical-stage biotechnology company in Canada. The company develops regenerative medicine therapeutics comprising proprietary Cell Pouch, a bio-hybrid organ system to replicate natural body functions. Its Cell Pouch creates vascularized organs for the longevity and functionality of therapeutic cells and ensures containment for retrievability. Sernova Biotherapeutics Inc was formerly known as Sernova Corp. and changed its name to Ser…
Full company profileSernova Corp financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Jul 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Sernova Corp annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | - | - | - | - | - | - | - | - |
| Operating Income | -2.50M | -2.64M | -3.71M | -4.01M | -5.26M | -6.94M | -24.8M | -40.5M | -31.7M | -15.0M | -8.71M |
| EBITDA | - | -2.59M | -3.62M | -3.90M | -5.01M | -6.64M | -23.9M | -38.5M | -31.1M | -14.6M | -8.72M |
| Net Income | -2.50M | -2.64M | -3.70M | -3.97M | -5.32M | -6.97M | -24.4M | -39.0M | -32.2M | -15.7M | -10.8M |
| EPS | - | -0.02 | -0.02 | -0.02 | -0.03 | -0.03 | -0.08 | -0.13 | -0.10 | -0.05 | -0.03 |
| Balance Sheet | |||||||||||
| Total Assets | 6.23M | 4.55M | 3.61M | 5.57M | 5.73M | 29.8M | 52.5M | 22.1M | 7.53M | 764K | 374K |
| Total Liabilities | 846K | 901K | 341K | 687K | 1.58M | 1.75M | 4.88M | 9.59M | 20.5M | 25.8M | 12.1M |
| Shareholders' Equity | 5.38M | 3.65M | 3.26M | 4.88M | 4.14M | 28.1M | 47.6M | 12.5M | -13.0M | -25.1M | -11.8M |
| Cash & Short-term Investments | 0.00 | 0.00 | 0.00 | 1.80M | 3.95M | 27.9M | 3.78M | 8.72M | 6.01M | 265K | 63.3K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -2.55M | -2.74M | -3.92M | -4.19M | -3.94M | -6.84M | -14.4M | -30.3M | -18.9M | -10.9M | -5.66M |
| Capital Expenditure | 19.4K | 252K | 115K | 24.0K | 5.47K | 17.2K | 329K | 99.3K | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | - | -2.99M | -4.03M | -4.22M | -4.94M | -6.86M | -14.8M | -30.4M | -18.9M | -10.9M | -5.66M |
| Ratios | |||||||||||
| ROE | -46.5% | -72.3% | -113.3% | -81.3% | -128.4% | -24.8% | -51.3% | -311.6% | - | - | - |
| ROA | -40.2% | -58.0% | -102.6% | -71.3% | -92.9% | -23.4% | -46.5% | -176.4% | -427.7% | -2,060.0% | -2,884.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Sernova Corp dividends
Sernova Corp has not paid dividends in the last 9 fiscal years.
Who owns Sernova Corp
- Insiders 10.51%
- Institutions 0.04%
- Public & others 89.45%
- Shares outstanding 378M
- Free float 337M
Sernova Corp company profile
- Company name
- Sernova Corp
- Ticker
- SEOVF.US
- ISIN
- CA81732W1041
- Exchange
- USA Stocks
- Listed since
- Apr 12, 1999
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 8
- Fiscal year end
- October
- Address
- RPO Central Parkway, Mississauga, ON, Canada, L5A 4H2
- Phone
- 917-751-5713
- Website
- sernova.com
About Sernova Corp
Sernova Biotherapeutics Inc operates as a clinical-stage biotechnology company in Canada. The company develops regenerative medicine therapeutics comprising proprietary Cell Pouch, a bio-hybrid organ system to replicate natural body functions. Its Cell Pouch creates vascularized organs for the longevity and functionality of therapeutic cells and ensures containment for retrievability. Sernova Biotherapeutics Inc was formerly known as Sernova Corp. and changed its name to Sernova Biotherapeutics Inc in February 2025. Sernova Biotherapeutics Inc is based in Mississauga, Canada.
Sernova Corp management
5- Mr. Jonathan M. N. Rigby M.B.A.President, CEO & Director · born 1968
- Mr. James T. Parsons CPA-CA, MAccChief Financial Officer · born 1965
- Ms. Marylyn RigbyChief Communications Officer
- Mr. David BurkeVice President of Investor Relations
- Dr. Patricia Beaston M.D., Ph.D.Sernova Biotherapeutics Inc.